XRAY in the 13F filings
Dentsply Sirona Inc · CUSIP 24906P109
- Quarter end
- 31 Mar 2024
- the date the book describes
- Filed
- 15 May 2024
- latest of these filings; the earliest 18 Apr 2024
- Managers listing it
- 12
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q4 2023 and Q1 2024; 10 listed it in both
- Shares listed
- 32,232,904
- combined, among listed positions
- Reported value
- $1.1bn
- combined, at the quarter end
Among the 93 comparable managers: 8 buyers (opened or added shares) and 5 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing XRAY in Q1 2024
12 of 12 holders
Largest increases and reductions, by shares
Increases
- Marshall Wace LLPexisting position · 2,134,571 shares now+987,515
- Arrowstreet Capital LPexisting position · 1,238,762 shares now+827,253
- T. Rowe Price Associates Incexisting position · 6,266,781 shares now+343,915
- Quantbot Technologies LPexisting position · 77,250 shares now+42,342
- PDT Partners LLCnew position · 18,323 shares now+18,323
Reductions
- Artisan Partners LPexisting position · 1,952,128 shares now-10,991,906
- Bridgewater Associates LPexisting position · 263,939 shares now-62,549
- Janus Henderson Group Ltdexisting position · 7,532,464 shares now-50,723
- First Eagle Investment Management LLCexisting position · 9,785,935 shares now-910
New positions and exits
New (1)
- PDT Partners LLC$608k
Exited (1)
- Winton Group Ltdwas $8.6m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2016 | 17 | $3.1bn | n.a. | n.a. |
| Q2 2016 | 18 | $3.0bn | n.a. | n.a. |
| Q3 2016 | 15 | $2.8bn | n.a. | n.a. |
| Q4 2016 | 14 | $2.7bn | n.a. | n.a. |
| Q1 2017 | 19 | $2.7bn | n.a. | n.a. |
| Q2 2017 | 13 | $2.6bn | n.a. | n.a. |
| Q3 2017 | 13 | $2.6bn | n.a. | n.a. |
| Q4 2017 | 12 | $2.6bn | n.a. | n.a. |
| Q1 2018 | 17 | $1.4bn | n.a. | n.a. |
| Q2 2018 | 12 | $933m | n.a. | n.a. |
| Q3 2018 | 18 | $1.6bn | n.a. | n.a. |
| Q4 2018 | 13 | $1.6bn | n.a. | n.a. |
| Q1 2019 | 13 | $1.8bn | n.a. | n.a. |
| Q2 2019 | 14 | $2.1bn | n.a. | n.a. |
| Q3 2019 | 16 | $1.9bn | n.a. | n.a. |
| Q4 2019 | 16 | $2.0bn | n.a. | n.a. |
| Q1 2020 | 16 | $1.5bn | n.a. | n.a. |
| Q2 2020 | 16 | $2.1bn | n.a. | n.a. |
| Q3 2020 | 14 | $2.3bn | n.a. | n.a. |
| Q4 2020 | 11 | $2.7bn | n.a. | n.a. |
| Q1 2021 | 16 | $3.7bn | n.a. | n.a. |
| Q2 2021 | 23 | $3.8bn | n.a. | n.a. |
| Q3 2021 | 18 | $3.3bn | n.a. | n.a. |
| Q4 2021 | 13 | $2.8bn | n.a. | n.a. |
| Q1 2022 | 16 | $2.8bn | n.a. | n.a. |
| Q2 2022 | 18 | $2.0bn | n.a. | n.a. |
| Q3 2022 | 17 | $1.5bn | n.a. | n.a. |
| Q4 2022 | 14 | $1.6bn | n.a. | n.a. |
| Q1 2023 | 11 | $2.2bn | n.a. | n.a. |
| Q2 2023 | 10 | $1.9bn | n.a. | n.a. |
| Q3 2023 | 15 | $1.7bn | n.a. | n.a. |
| Q4 2023 | 13 | $1.7bn | 9 | 7 |
| Q1 2024 | 12 | $1.1bn | 8 | 5 |
| Q2 2024 | 9 | $781m | 7 | 3 |
| Q3 2024 | 8 | $941m | 6 | 2 |
| Q4 2024 | 9 | $648m | 8 | 2 |
| Q1 2025 | 9 | $586m | 8 | 2 |
| Q2 2025 | 8 | $639m | 3 | 6 |
| Q3 2025 | 6 | $369m | 4 | 2 |
| Q4 2025 | 5 | $199m | 23 | 9 |
| Q1 2026 | 7 | $273m | 17 | 17 |
| Q2 2026 | 5 | $61m | 10 | 19 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
XRAY and LLY →XRAY and JNJ →XRAY and VRTX →Choose a stock to compare with XRAY →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own XRAY, latest filings →Back to the 13F Explorer →